Alignment Healthcare vs Oscar Health
ALHC and OSCR side by side, both in accident and health insurance and medical. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALHC and OSCR compare
Oscar Health is the larger company, worth 6.2 times as much as Alignment Healthcare ($9.4B against $1.5B).
On earnings, Oscar Health is cheaper: it trades at 21.7× trailing earnings, against 66.1× for Alignment Healthcare.
Oscar Health grew revenue faster over the last twelve months (42.8% versus 35.9% for Alignment Healthcare).
Oscar Health keeps more of each dollar of sales as profit, with a net margin of 3.6% compared with 0.59% at Alignment Healthcare.
Oscar Health scores higher on the StockData Score (11 against 9 for Alignment Healthcare), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALHC | OSCR |
|---|---|---|
| Size and price | ||
| Market cap | $1.5B | $9.4B |
| Share price | $7.27 | $30.37 |
| Change, 1 year | −60.1% | 60.6% |
| Change, 5 years | −67.1% | 78.6% |
| Beta (5Y) | 0.81 | 1.65 |
| Employees | 1,849 | 2,305 |
| StockData Score | ||
| Total score | 9 | 11 (better) |
| Valuation score | 1 | 1 |
| Growth score | 2 | 2 |
| Performance score | 3 | 4 (better) |
| Health score | 3 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 66.1× | 21.7× (better) |
| P/S | 0.3× (better) | 0.6× |
| P/B | 5.4× | 4.6× (better) |
| EV/EBITDA | 14.5× | 1.9× (better) |
| P/FCF | 19.6× | 2.1× (better) |
| FCF yield | 5.1% | 46.7% (better) |
| Fair value | $5.01 | $23.67 |
| Margin of safety | −45.0% | −28.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 35.9% | 42.8% (better) |
| Revenue growth, 5Y average | 32.7% | 90.8% (better) |
| Profitability | ||
| Operating margin | 0.88% | 4.1% (better) |
| Net margin | 0.59% | 3.6% (better) |
| FCF margin | 1.6% | 28.6% (better) |
| Return on equity | 13.2% | 34.3% (better) |
| Financial health | ||
| Debt / equity | 1.17 | 0.21 (better) |
| Net debt / EBITDA | −5.57 | −12.35 |
| Interest coverage | 2.6× | 39.7× (better) |
| Current ratio | 1.71 (better) | 1.08 |
| Altman Z-score | 4.22 (better) | 1.95 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 107% | 64.7% |
| Held by insiders | 4.6% | 20.9% |
| Insider net buying, 12 months | −$520M | −$138M (better) |
| Short interest, % of float | 11.9% | 6.7% |
Go deeper
- ALHC stock overview
- ALHC income statement
- ALHC valuation and score
- OSCR stock overview
- OSCR income statement
- OSCR valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.